COVID-19 (Coronavirus) Update

A Phase I/II Study of TheraT® Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients with HPV 16+ Confirmed Cancers

Protocol No
HOOKIPA-H-200-001
Principal Investigator
Stuart Wong
Phase
I/II
Summary
In this study, different regimens of the study drug are planned to be explored to see which regimen is safe and works the best: • HB-201 alone • A regimen of HB-201 alternating with HB-202 • HB-201 in combination with an FDA-approved drug, Nivolumab • A regimen of HB-201 alternating with HB-202, in combination with an FDA-approved drug Nivolumab
Description
This study is to investigate the study drug in patients with a specific type of cancer called human papillomavirus 16-positive (HPV 16+) cancers. HPV 16+ cancers include head and neck, cervical, anal, vaginal, vulvar, and penile cancers. The main goal of the study is to determine whether HB-201 and HB-202 are effective in the treatment of human papillomavirus 16 positive (HPV 16+) confirmed cancers.
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: